27 Oct 2022

(English)THE EXCHANGE PUBLISHED THE CONSULTATION PAPER ON LISTING REGIME FOR SPECIALIST TECHNOLOGY COMPANIES

Introduction

On 19 October 2022, The Stock Exchange of Hong Kong Limited (the “Exchange”) published a consultation paper on the proposed amendments to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) in relation to a Listing Regime for Specialist Technology Companies (the “Consultation Paper”). In particular, the Exchange seeks to create a new Chapter 18C to govern the listing of Specialist Technology Companies, taking into consideration of the high growth potential of Specialist Technology Companies (“STCs”).1 The Exchange is seeking market feedback on its proposals by 18 December 2022.

Definition of “Specialist Technology Companies”

A broad definition is adopted so as to reserve the Exchange’s flexibility to publish and update the guidance letter as specialist technology industries (“Specialist Technology Industries”) evolve over time. STC is proposed to be defined as “a company primarily engaged (whether directly or through its subsidiaries) in the research and development of, and the commercialisation and/or sales of, specialist technology products within an acceptable sector of a Specialist Technology Industry”.2

A non-exhaustive list of Specialist Technology Industries and acceptable sectors will be published and updated from time to time. The proposed industries are set out as follows:3

(i) Next-generation information technology;
(ii) Advanced hardware;
(iii) Advanced materials;
(iv) New energy and environmental protection; and
(v) New food and agriculture technologies.

The Exchange proposes not to limit eligible applicants to those with “leading-edge” technologies. This aligns with the stakeholders’ view that the success of a STC is often attributable to the successful commercialisation of the core technology rather than the innovativeness of the technology itself. Moreover, companies with multiple business segments are included in the proposed listing regime for STCs, provided that they are “primarily engaged” in the relevant business (as referred to in the definition of STC).4

Background Issues

The Exchange recognises the necessity to regulate STCs since they pose particular regulatory issues:5

Difficulty in reaching a consensus on valuation
  • STCs often operate in new markets at the early stages and thus it is difficult to predict the potential market size of the products and how successful the company will be in addressing the needs of that market.
  • Moreover, since some STCs have not commercialised their products, they are subject to risks of speculation and manipulation of their valuation. They may also modify their business models significantly which leads to share price volatility and/or trading illiquidity after listing.
  • Absence of a Competent Authority
  • The Competent Authority regime for Biotech Companies for example provides investors with a frame of reference for investors to judge the stage of development of the products, in the absence of commercial indicators.
  • However, the products of STCs are not usually required to be evaluated or approved by a Competent Authority.
  • The Exchange is also not in a position to vet or assess the truth or accuracy of the claims made by STCs in their Listing Document. Therefore, this places investors at a risk of misrepresentation.
  • Viability of a product or service
  • Since novel technology may be applied, special expertise is necessary to assess the capabilities of their products.
  • There is a risk of companies intentionally overstating these capabilities, and deficiencies in the capabilities may not be uncovered until commercialisation.
  • Failure to successfully commercialise
  • STCs may fail to successfully commercialise, since many of them are still in the early stage and are engaging in R&D to commercialise their product.
  • Reliance on external funding
  • STCs rely on external funding to support operations. Since these companies have not yet generated sufficient revenue, they would fund their working capital requirements through proceeds from equity or debt financing.
  • Moreover, additional funding might be sought by the companies after listing, resulting in dilution of existing shareholders’ ownership interest.
  • Categorisation into Commercial and Pre-Commercial Companies

    The Exchange proposes that STCs will be categorised into “Commercial” and “Pre-Commercial” companies, with revenue threshold as a “bright line” test. 6

    “Commercial Companies” are those that have achieved meaningful commercialisation of their Specialist Technology Products and achieved a minimum revenue of HK$250 million in the most recent audited financial year, and are also expected to demonstrate year-on-year growth of revenue from the Specialist Technology Business. 7 Pre-Commercial companies will be subject to more stringent requirements as stated below. 8

    Requirements

    The below table sets out a comparison of the key requirements for Commercial Companies and Pre-Commercial Companies to be eligible for listing as set out in the Consultation Paper: 9

    Commercial Companies Pre-Commercial Companies

    Qualifications for Listing
    Expected market
    Capitalisation
    At least HK$8 billion at the time of listing Qualifications for Listing
    At least HK$15 billion at the time of listing
    Revenue Threshold At least HK$250 million arising from the company’s Specialist Technology business segment(s) for the most recent audited financial year No requirement
    Research and Development (R&D) Engaged in R&D for at least three financial years
    R&D investment constitutes at least 15% of total operating expenditure for each of the three financial years prior to listing R&D investment constitutes at least 50% of total operating expenditure for each of the three financial years prior to listing
    Operational track record At least three financial years of operation under substantially the same management prior to listing
    Third-party investment Definition of Sophisticated Independent Investors (“SIIs”):

    (a) must not be a core connected person of the listing applicant (excluding a person being connected only by virtue of being a substantial shareholder); and

    (b) must be a sophisticated investor who meets any of the indicative size thresholds or qualification requirement

    Minimum investment requirements:
    The listing applicant must have received meaningful investment from SIIs, with the following indicative benchmark which must be met:

  • investment from at least two SIIs at least 12 months prior to the date of the listing application, each holding such amount of shares or securities convertible into shares equivalent to 5% or more of the issued share capital of the listing applicant as at the date of listing application and throughout the preapplication 12-month period (“Pathfinder SIIs”); and
  • at least the following aggregate investment from all SIIs as at the time of listing of:
  • Expected market
    capitalisation
    at the time of listing
    (HK$)
    Minimum total
    investment
    (as % of issued share
    capital) at
    time of listing
    ≥ 8 billion to < 20 billion 20%
    ≥ 20 billion to < 40 billion 15%
    ≥ 40 billion 10%
    Minimum total
    investment
    (as % of issued share
    capital) at
    time of listing
    ≥ 15 billion to < 20 billion 25%
    ≥ 20 billion to < 40 billion 20%
    ≥ 40 billion 15%

    IPO Requirements
    More robust price discovery process
  • Allocate at least 50% of the total number of shares offered in IPO to Independent Institutional Investors
  • Revised initial allocation and clawback mechanism as follows:
    Initial No. of times (x) of over-subscription in
    the public placing tranche
    ≥ 10x to < 50x ≥ 50x
    Minimum allocation to retail investors as % of
    total shares offered in IPO
    5% 10% 20%
  • Requirements on free float and offer size
  • Free float: minimum free float (being shares not subject to any disposal restrictions) of at least HK$600 million upon listing;
  • Offer size: the Exchange would expect the listing of a Specialist Technology Company to be accompanied by an offer (including both the placing tranche and the public subscription tranche) of a meaningful size and reserves the right not to approve the listing if the offer size is not significant enough to facilitate post-listing liquidity, or otherwise gives rise to orderly market concerns.
  • Disclosure requirements
  • Additional disclosure requirement in the Listing Document to facilitate IPO investors’ assessment of a STC, including: (a) pre-IPO investments and cash flows; (b) products and commercialisation status and prospects; (c) R&D; (d) industry specific information; and (e) intellectual property.
  • A warning statement in its Listing Document that the applicant is a Specialist Technology Company and so investment in its securities carries additional risks.

  • Post-IPO Requirements
    Post-IPO lock-up
  • Post-IPO lock-up on the following persons:
    (a) controlling shareholders of the listing applicant;

    (b) key persons including founders, any weighted voting rights (“WVR”) beneficiaries, executive directors and senior management, and key personnel responsible for the technical operations and/or R&D; and

    (c) Pathfinder SIIs.

  • Continuing obligations for Pre-Commercial Companies (until achieving the
    Commercialisation
    Revenue
    Threshold)
    Not applicable
  • Additional disclosure in the interim and annual reports including the timeframe for, and any progress made towards, the issuer achieving the Commercialisation Revenue Threshold; and updates on any revenue, profit and other business and financial estimates as provided in the Listing Document (and any subsequent updates to those estimates as published by the Pre-Commercial Company)
  • Shortened remedial period of 12 months (rather than the usual 18 months) for re-compliance with the sufficiency of operations requirement before delisting
  • Restricted from effecting any transaction that would constitute a material change of business without the prior consent of the Exchange
  • Identified through the stock marker “PC”
  • Analysis and Takeaways

    Since 2018, the Exchange has been active in implementing listing reforms, which range from permitting the listing of pre-revenue biotech companies, the listing of WVR Issuers that are considered innovative, to the creation of a new concessionary secondary listing route for overseas issuers listed on a qualifying exchange.

    However, it is considered that Hong Kong still lags behind the US and Mainland China in terms of the number and market capitalisation of STCs (or their equivalent), which was explained by (i) the difficulty of Pre-Commercial Companies to meet the profit, revenue or cash flow requirements of the Exchange’s Main Board eligibility tests; and (ii) that Commercial Companies are often not able to meet the Main Board tests. It is therefore crucial to develop a listing regime which is friendlier to STCs since there is a strong appetite among investors to invest in these companies due to their high growth potential, 10 which in turn increase the competitiveness of the Hong Kong market and promote Hong Kong as a fundraising and technology hub of the Greater Bay Area.

    Please contact our Mr. Rodney Teoh (Partner) and our Calvin KW Lo (Paralegal (pending admission)) for any enquiries or further information.

    This news update is for information purposes only. Its content does not constitute legal advice and should not be treated as such. Stevenson, Wong & Co. will not be liable to you in respect of any special, indirect or consequential loss or damage arising from or in connection with any decision made, action or inaction taken in reliance on the information set out herein.

    1 Consultation Paper, appendix IV, at IV-4
    2 Consultation Paper p. 29
    3 Consultation Paper p. 30
    4 Consultation Paper p. 32
    5 Consultation Paper pp. 3 to 4
    6 Consultation Paper p. 34
    7 Consultation Paper pp. 4, 39 to 40
    8 Consultation Paper p. 35
    9 Consultation Paper pp. 5-10
    10 Consultation Paper pp. 2-3

    25 Oct 2022

    [Hybrid Seminar Registration] Walk through the end-to-end journey in Cyber Risk Management to get you up to speed

    Enterprises believe Cyber-Security solutions nowadays are able to tackle the problems all in one, but there are other comprehensive solutions that can provide particular solutions as well. To Know more about the needed configurations and necessary steps to equip yourself in nowadays Cyber Risk Management.

    We are going to have a hybrid seminar coming up to walk through the takeaway points from each Cyber Risk. A better reference for you to navigate through this Cyber Security journey. What are these cyber-attacks and how to navigate through the World with Datastore on Cloud/On-Premise options?

    Details:
    Date: 4 Nov 2022 (Friday)
    Time: 1pm to 2pm
    Speakers:
    Mr. Anthony Cheung | Director of TechMem (Hong Kong) Limited
    Ms. Milly Hung | Partner, Stevenson, Wong & Co.
    Mr. Michael Lau | Senior Associate, Stevenson, Wong & Co.
    Language: English
    Fee: Free
    Registration method:
    This hybrid seminar will take place at our office and live stream on Zoom.
    Venue: 39/F, Gloucester Tower, the Landmark, Central
    Online: Zoom
    Please scan the QR codes in the poster below to register.

    Contents:

    • What are at risk? (From Cyberattacks, e.g. Data, Operations, etc.)
    • What is the blast radius? (Penalty, Reputations, Commercial Loss)
    • How did it happen? (What’s baking behind?)
    • What are the measures nowadays to tackle them?
    • What’s the mentality when addressing Cyber Risk in your own company?
    • What are the guidelines and regulations from HKMA and HKIA to contain the risk? (Tackling AML, GDPR, and Regional Handshake)

    We shall go through all of these points in the upcoming webinar and give references and real-life examples of how these impacts are prevented, in particular from an experienced Cyber-Security Lead in FSI (Financial Service Industry) to walk through the measures and expertise in this area.

    By the end of the webinar, participants could sign up for free Cyber Risk Assessments to indicate the Cyber Risks (How did it handle now and what is suggested) in your unique IT environment.

    For any inquiries, please contact us at: marketing@sw-hk.com.

    24 Oct 2022

    Partner Milly Hung and Senior Associate Michael Lau Invited by the Law Society of Hong Kong as Webinar Speakers

    On 18 October 2022, our Partner Milly Hung and Senior Associate Michael Lau were invited by the Law Society of Hong Kong to be the webinar speakers of “Litigation in Cybercrime”.

    Our Partner Milly Hung (on the right) and Senior Associate Michael Lau (on the left)

    By highlighting the common cybercrime in Hong Kong, Milly and Michael has led the participants to go through various common civil and criminal actions against the cybercrime fraudsters. To handle the aftermath, they shared their previous experiences about the “Letter of No Consent” Regime and the ways to trace and claim back the assets that have been misappropriated as a result of the Cybercrime.

    For more information, please contact our Partner Milly Hung.

    20 Oct 2022

    (中文) 史蒂文生黄律师事务所获香港中资银行业协会委任为法律事务委员会顾问

    (中文) 本所荣幸获香港中资银行业协会 (以下简称 “协会” ) 委任为法律事务委员会顾问, 并与协会其他专业委员会之委员和法律顾问共同参与委任状之颁赠仪式。该典礼于2022年10月17日在中国银行大厦举行。本所合伙人、银行与金融部和诉讼与争议解决部主管徐凯怡律师受邀出席。此外,协会其他专业委员会之顾问单位,包括德勤 (Deloitte) ﹑普华永道 (PwC) ﹑安永 (EY) 和毕马威 (KPMG) 的代表亦参与了委任仪式。


    左起: 立法会议员、香港中资银行业协会法律事务委员会执委会主任简慧敏女士、本所合伙人徐凯怡律师、立法会议员(金融界)、香港中资银行业协会副会长兼秘书长陈振英先生

    徐律师就本次委任表示: 非常荣幸我所获香港中资银行业协会委任为法律顾问,为协会之法律事务﹑会务和业界未來发展提供支持,贡献微薄的力量。期待日后与各专业委员会之委员和会员,有更多的交流和合作。祝愿协会未來的工作成果丰硕,会务蒸蒸日上!

    关于香港中资银行业协会

    香港中资银行业协会为2016年于香港注册成立的非牟利社团,由中国银行(香港)有限公司、中国工商银行(亚洲)有限公司、中国农业银行股份有限公司香港分行、中国建设银行(亚洲)股份有限公司、交通银行股份有限公司香港分行及国家开发银行香港分行6家机构共同发起。协会会员主要为中资银行,亦吸纳业界不同背景的会员。

    关于法律事务委员会

    法律事务委员会为香港中资银行业协会辖下的专业委员会之一,其职责包括: 协助会员了解相关法律要求,防范法律风险和构建会员在法律专业范畴的统一沟通协调平台。此外, 亦包括就与银行业务有关的立法或对业界发展有重大影响的法律咨询事项收集会员意见并提交予相关机构,以及与内地、香港及其他相关国家/地区的法律界建立工作联系等。

    如阁下有任何查询或想了解更多详情,请联络本所合伙人徐凯怡律师

    18 Oct 2022

    Partner Gordon Tsang at LexisNexis 40 UNDER 40 Award Ceremony Luncheon

    LexisNexis recently announced the winners of 40 under 40. Our Partner Gordon Tsang was recognised as one of the winners of LexisNexis 40 UNDER 40 and invited to attend the award ceremony luncheon held at The China Club on 14 October 2022.

    The inaugural award aims to recognize 40 young talent aged 40 years old or under across various legal fields in mainland China, Hong Kong, Macau and Taiwan. Winners are selected for delivering the best and best-in-class work ethics to their clients, partners, and colleagues together with showing exceptional passion to grow and lead the development of the legal sector in Greater China.

    Gordon Tsang | Partner
    Practice Areas: China Practice, Corporate Commercial Law, Corporate Services, Corporate Finance

    Gordon has experience handling a wide range of corporate and commercial matters, including pre-IPO restructuring and financing, Hong Kong and U.S. IPOs, mergers and acquisitions, loan and financing transactions, corporate governance and general compliance for listed companies as well as private enterprises.

    Gordon is a Non-Executive Director of China Regenerative Medicine International Ltd (Stock Code: 8158), the Independent Non-Executive Director of Sterling Group Holdings Limited (Stock Code: 1825) and CROSSTEC Group Holdings Limited (Stock Code: 3893). He is also the Company Secretary of 1957 & Co. (Hospitality) Limited (Stock Code: 8495), Sunshine 100 China Holdings Ltd (Stock Code: 2608), Mabpharm Limited-B (Stock Code: 2181) and Sundy Service Group Co. Ltd (Stock Code: 9608).

    Gordon has successfully assisted Magic Empire Global Limited (NASDAQ: MEGL), Intelligent Living Application Group Inc. (NASDAQ: ILAG), Zhong Yang Financial Group Limited (NASDAQ: TOP), Hywin Holdings Ltd. (NASDAQ: HYW) and Oriental Culture Holding Ltd (NASDAQ: OCG) on their NASDAQ listing.

    For more information, please contact our Partner Gordon Tsang or visit Gordon’s profile on LexisNexis 40 UNDER 40 here.

    17 Oct 2022

    Stevenson, Wong & Co. advises Jiangmen City Haina New Energy Investment Partnership (Limited Partnership) on its cornerstone investment in the listing of CALB Co., Ltd. (Stock Code: 3931)

    Stevenson, Wong & Co. advised Jiangmen City Haina New Energy Investment Partnership (Limited Partnership) (江門市海納新能源投資合夥企業 (有限合夥)) (“Jiangmeng New Energy”) on its cornerstone investment in the global offering of CALB Co., Ltd. (中創新航科技股份有限公司) (Stock Code: 3931) (“CALB”).

    CALB was officially listed on the Main Board of The Stock Exchange of Hong Kong Limited on 6 October 2022 and has raised HK$9.9 billion from its initial public offering, making it the third-largest initial public offering by fund raised in Hong Kong this year. CALB’s market capitalisation upon listing was HK$10.1 billion. CALB is a leading new energy technology company mainly engaged in the design, research and development, production and sales of EV batteries and ESS products. CALB is one of the top 10 companies in the global EV battery industry and is the third-largest EV battery maker in the PRC.

    Jiangmen New Energy is a limited liability partnership established under the laws of the PRC and is principally engaged in the investment in the new energy industry with its own funds. The ultimate beneficial owner of Jiangmen New Energy is the Administration Commission of Jiangmen City (江門市人民政府國有資產監督管理委員會). Jiangmen New Energy invested in RMB700 million as cornerstone investment in CALB, making it the single largest cornerstone investor in value in the listing of CALB.

    The SW team was led by corporate Partner Mr. Hank Lo and Senior Associate Mr. Terence Lau, supported by Paralegal Ms. Bethany Zhang.

    Please contact Mr. Hank Lo or Mr. Terence Lau for any enquiries or further information about this transaction.